SCHEMBL6312924

SCHEMBL6312924

CCN(C(=O)OC(C)(C)C)C(C)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
ITGA4 P13612 1/20 0.43
ITGB7 P26010 1/20 0.43
CTSS P25774 2/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSK P43235 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2A P28223 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRK1 P41145 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9190936 0.87 MAOB (0.48) ATMITGA4ITGB7CTSSCTSL
SCHEMBL9188157 0.87 MAOB (0.48) ATMITGA4ITGB7CTSSCTSL
SCHEMBL9191801 0.85 L3MBTL1 (0.44) ATMITGA4ITGB7CTSSCTSL
SCHEMBL9191804 0.85 L3MBTL1 (0.44) ATMITGA4ITGB7CTSSCTSL
SCHEMBL23099848 0.84 ATM (0.42) ATMITGA4ITGB7CTSSCTSL
SCHEMBL10957821 0.84 ATM (0.42) ATMITGA4ITGB7CTSSCTSL
SCHEMBL10957808 0.84 ATM (0.42) ATMITGA4ITGB7CTSSCTSL
SCHEMBL9192340 0.84 ALDH1A1 (0.43) ATMITGA4ITGB7L3MBTL1MAOB
SCHEMBL4441034 0.82 ATM (0.45) ATMITGA4ITGB7CTSSCTSL
SCHEMBL12050814 0.82 BCHE (0.53) ATMITGA4ITGB7CTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS CORPORATION 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 ATM 4251/4885ITGA4 4703/4885ITGB7 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.